Accéder au contenu
Merck

Effects of lidoflazine on left ventricular function in patients.

Journal of cardiothoracic and vascular anesthesia (1997-02-01)
S G De Hert, I E Rodrigus, L R Haenen, P W Ten Broecke, C J Boeckxstaens, T C Gillebert
RÉSUMÉ

The present study evaluated the effects of the nucleoside transport inhibitor, lidoflazine, at a dose of 1 mg/kg, on left ventricular function. Patients were randomly assigned to receive either lidoflazine or saline in a double-blind manner. A university hospital. The study was performed in 32 patients scheduled for elective coronary artery bypass surgery. Left ventricular pressures were measured with fluid-filled catheters. Data were digitally recorded during pressure elevation induced by tilt-up of the legs. Transgastric short-axis echocardiographic views of the left ventricle were simultaneously recorded on videotape. Systolic function was evaluated with the slope (Ees, mmHg/mL) of the systolic pressure-volume relationship. Diastolic function was evaluated with the chamber stiffness constant (Kc, mmHg/mL) of the diastolic pressure-volume relationship. Cardiac function was assessed at baseline and after administration of either lidoflazine (group A [n = 16]) or placebo (group B [n = 16]). Data were compared using two-factor analysis of variance. At baseline, diastolic and systolic function were comparable in both groups. Lidoflazine increased Kc from 0.079 +/- 0.015 to 0.125 +/- 0.017 mmHg/mL and decreased Ees from 2.481 +/- 0.213 to 1.217 +/- 0.211 mmHg/mL (p = 0.009 and p = 0.004, respectively). None of these changes occurred when placebo was administered. Administration of lidoflazine before the start of cardiopulmonary bypass impaired left ventricular systolic function but also increased diastolic stiffness.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Lidoflazine, ≥98% (HPLC), powder